Biologic Pharmamedical announced today that it has received approval by Health Canada’s NNHPD and a Natural Product Number (NPN) for its market-proven Curcumin BioBDMC30™ and variable offshoot technologies including others with condition specific-indications. This research-supported, patented technology delivers an exceptionally high concentration – 30% – of bisdemethoxycurcumin (BDMC), which is designed to help manage inflammation, joint pain, and discomfort, and support recovery from day-to-day workouts or injuries utilizing very unique pharmacology that differentiates it significantly from regular curcumin 95%.
This highly potent anti-inflammatory offers 60x more BDMC than most products, providing immense joint pain relief and more rapid recovery from inflammation caused by injuries and exercise. The recent discovery made in a Canadain laboratory as a function of more than a decade of research also exhibits a profound antioxidant potential never seen before on the planet jumping the ORAC value for Curcumin BioBDMC30™ to an unprecedented 1,130,000 mM/TE per 600 mg.
Curcumin BioBDMC30™ is based on research by Biologic Pharmamedical Research (www.biologic-med.com) CEO, Franco Cavaleri BSc Ph.D. Candidate, who is also the principal research scientist at Biologic Pharmamedical. For the first time, Cavaleri’s research shows how the modified curcumin extracts targets and neutralizes a key protein central in the regulation of inflammation while significantly enhancing the anti-inflammatory properties of curcumin. This genomic and proteomic research model was designed by this Canadian scientist to ultimately serve as a model that has shed light on the activity of other curcuminoids in the context of other important drug targets.
“Research shows that BDMC targets inflammation in a novel way inhibiting MSK1 an activation protein that turns on the production of inflammatory cytokines while regular curcumin simply cannot neutralize this protein,” said Cavaleri. “Instead of trace levels of BDMC, usually between 0.5% and 1.5%, in standard curcumin, we can now provide 30% BDMC and dramatically enhance anti-inflammatory relief, which could not be done reliably before.” Cavaleri goes on to say. “Regular curcumin 95% can slow down NF-kB transcription protein activity but it cannot inhibit MSK1.”
This new curcumin research has demonstrated effective modulation of survival proteins in difficult to treat diseases. Regular curcumin inhibits only one key inflammatory protein of the two inflammatory proteins Curcumin BioBDMC30™ neutralizes. BDMC engineering is also revealing a faster symptom resolution time in cases of dysregulated inflammation and joint pain when compared to typical curcumin.
Cavaleri’s research at the Canadian-based Biologic Pharmamedical Research is focused on defining ways to improve clinical and research reliability using curcumin-based drugs as supplements or alternatives to glucocorticoids for glucocorticoid-resistant inflammatory diseases, and to chemotherapy for drug-resistant cancers. This Canadian researcher in the Canadian laboratory has changed the way the world now views and designs curcuminoid-based technologies. This discovery has set in motion multiple new findings related to new drug targets by the scientist for curcumin that leverages this curcuminoid engineering. A second technology relating to this isolated curcuminoid research about to be announced focusses in on cholesterol management with similar mechanisms to common statin drugs but without the side-effects. Cavaleri’s research in this field has recently been published in peer-reviewed publications further validating the novel findings and he says Biologic Pharmamedical Research has more exciting findings on other botanical agents relating to diabetes and obesity about to be made public.
